ArticleJournal of virology2003
Replicating parvoviruses that target colon cancer cells.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Oncolytic Viruses for Canine Cancer Treatment.Cancers · 2018Review
- The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.Frontiers in oncology · 2017Article
- Transcriptome profiling indicating canine parvovirus type 2a as a potential immune activator.Virus genes · 2016Article
- VP2 capsid domain of the H-1 parvovirus determines susceptibility of human cancer cells to H-1 viral infection.Cancer gene therapy · 2015Article
- Oncolytic parvoviruses: from basic virology to clinical applications.Virology journal · 2015Review
- Article
- Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids.Journal of virology · 2013Article
- Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells.OncoTargets and therapy · 2013Article
- TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells.PloS one · 2013Article
- Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.Journal of virology · 2012Article
- Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.BMC cancer · 2011Article
- Mechanisms of cell death in canine parvovirus-infected cells provide intuitive insights to developing nanotools for medicine.International journal of nanomedicine · 2010Article
- Modular Cre/lox system and genetic therapeutics for colorectal cancer.Journal of biomedicine & biotechnology · 2009Review
- Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.Journal of molecular medicine (Berlin, Germany) · 2008Review
- Exploring the contribution of distal P4 promoter elements to the oncoselectivity of Minute Virus of Mice.Virology · 2007Article
- Targeting of autonomous parvoviruses to colon cancer by insertion of Tcf sites in the P4 promoter.Cancer gene therapy · 2006Article
- Replication-selective oncolytic viruses in the treatment of cancer.Cancer gene therapy · 2005Review
- Pharmacological and genetic modulation of Wnt-targeted Cre-Lox-mediated gene expression in colorectal cancer cells.Nucleic acids research · 2004Article
- Modulation of minute virus of mice cytotoxic activities through site-directed mutagenesis within the NS coding region.Journal of virology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The wnt signaling pathway is constitutively activated in colon tumors by mutations in the adenomatous polyposis coli and beta-catenin genes. We have modified the minute virus of mice (MVM) P4 promoter to make it responsive to wnt signaling by inserting binding sites for the heterodimeric beta-catenin/Tcf transcription factor. In luciferase assays we can see up to 20-fold selectivity of Tcf mutant P4 promoters for cells with activated wnt signaling. Hybrid MVM/H-1 viruses containing Tcf mutant promoters were tested for NS1 expression, viral DNA replication, virus replication, and cytopathic effect on colon, lung, kidney, and cervical cancer cell lines. Activation of the wnt pathway by expression of Delta N-beta-catenin increased NS1 expression and viral burst size in 293T and H1299 lung cancer cells, showing that the Tcf mutant P4 promoter can respond to wnt signals in the context of the virus. Compared to the parental virus, the burst size of the Tcf mutant viruses was reduced at least 1,000-fold in H1299, 293T, NB324K, and HeLa cells, which have inactive wnt signaling pathways. The burst size and cytopathic effect of the Tcf viruses was near wild-type levels in SW480 and Isreco1 colon cancer cell lines, which have high Tcf activity. The high specificity of these viruses should permit the development of H-1 virus-based vectors which combine high safety and greater efficacy in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.